Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: Based on Data from the Medical Research Council LU19 Trial

Author： Bojke Laura  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.5, 2006-01, pp. : 443-452

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Granulocyte Colony-Stimulating Factor for Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer: The 40% Rule Revisited

By Calhoun Elizabeth A.  

PharmacoEconomics, Vol. 23, Iss. 8, 2005-01 ,pp. : 767-775

Adis International

Access to resources Recommend Favorite

Lenograstim + chemotherapy for small cell lung cancer: cost effectiveness "finely balanced"

By  

Inpharma, Vol. 1, Iss. 1542, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

By Griffiths Robert I.   Barron Richard L.  

PharmacoEconomics, Vol. 30, Iss. 2, 2012-02 ,pp. : 103-118

Adis International

Access to resources Recommend Favorite

Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care

By Pettengell Ruth  

Clinical Drug Investigation, Vol. 29, Iss. 8, 2009-08 ,pp. : 491-513

Adis International

Access to resources Recommend Favorite

Dose intensification in small cell lung cancer chemotherapy

By Middleton M.   Thatcher N.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 293-302

Informa Healthcare

Access to resources Recommend Favorite